1-4 of 4
William Pullman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Monotherapy Treatment with Zaltenibart (OMS906), an Alternative Pathway Masp-3 Inhibitor, Improved Key Hematologic Parameters in Patients with PNH with a Suboptimal Response to Ravulizumab: Interim Results from a Phase 2 Proof-of-Concept Study

Morag Griffin, Richard J. Kelly, Mathilde Gavillet, Petra Muus, Britta Hoechsmann, W. Jason Cummings, John Efthimiou, William Pullman, Hubert Schrezenmeier, Jens Panse
Journal: Blood
Blood (2024) 144 (Supplement 1): 4072.
https://doi.org/10.1182/blood-2024-205866
Published: 2024
Journal Articles

Population Pharmacokinetics/Pharmacodynamics and Clinical Pharmacology of Zaltenibart (OMS906) in Healthy Subjects and Patients with PNH

W. Jason Cummings, Yi Li, Siobhan Hayes, Richard Mills, Colm Farrell, Morag Griffin, J. Steve Whitaker, William Pullman
Journal: Blood
Blood (2024) 144 (Supplement 1): 4081.
https://doi.org/10.1182/blood-2024-206009
Published: 2024
Journal Articles

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Alternative Pathway Masp-3 Inhibitor OMS906 in a Phase 1 Study of Healthy Subjects

William Pullman, Jane Humphreys, Edward Philpot, W. Jason Cummings
Journal: Blood
Blood (2022) 140 (Supplement 1): 5801–5802.
https://doi.org/10.1182/blood-2022-162828
Published: 2022
Journal Articles

Trial in Progress: An Open-Label, Multi-Center Phase 2 Study Evaluating Efficacy and Safety of the Masp-2 Inhibitor Narsoplimab in Pediatric Patients with High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)

William Pullman, Mary Brough, Carolina Soto, Tze-Chiang Meng
Journal: Blood
Blood (2022) 140 (Supplement 1): 8493–8494.
https://doi.org/10.1182/blood-2022-155820
Published: 2022